Randomized Phase 2 Study of DKN-01 Plus FOLFIRI/FOLFOX and Bevacizumab Versus FOLFIRI/FOLFOX and Bevacizumab as Second-line Treatment of Advanced Colorectal Cancer (DeFianCe)

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Colorectal Cancer
  • Age: Between 18 Year(s) - 100 Year(s)
  • Gender: Male or Female
  • Other Inclusion Criteria:
    1. If assigned to receive FOLFIRI, patient may have received no prior irinotecan as part of first-line systemic therapy
    2. If assigned to receive FOLFOX, patient may have received no prior oxaliplatin as part of first-line systemic therapy
    3. Prior treatment with an anti-VEGF or anti-EGFR therapy is allowed as first-line and/or maintenance systemic therapy

You may not be eligible for this study if the following are true:

    1. Microsatellite instability-high (MSI-H)/mismatch repair-deficient (dMMR) and/or BRAF V600E mutation positive colorectal cancer
    2. Prior therapy with an anti-DKK1 agent
    3. Prior therapy with FOLFOXIRI



If you are registered as a volunteer, please log in to contact the study team/express interest in this study.